$ELOX
Eloxx Pharmaceuticals, Inc.

2012 Q2 Form 10-Q Financial Statement

#000114420412028430 Filed on May 14, 2012

View on sec.gov

Income Statement

Concept 2012 Q2 2012 Q1 2011 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $530.0K $500.0K $630.0K
YoY Change -15.87% -5.66% 8.62%
% of Gross Profit
Research & Development $640.0K $540.8K $590.0K
YoY Change 8.47% -32.43% -46.85%
% of Gross Profit
Depreciation & Amortization $70.00K $70.00K $30.00K
YoY Change 133.33% 75.0% -25.0%
% of Gross Profit
Operating Expenses $1.250M $540.8K $1.250M
YoY Change 0.0% -32.43% -27.75%
Operating Profit -$1.109M
YoY Change -18.94%
Interest Expense $130.0K -$27.98K $130.0K
YoY Change 0.0% 32.41% -102.9%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 $0.00
YoY Change
Pretax Income -$1.440M -$1.060M -$2.710M
YoY Change -46.86% -24.29% -56.36%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.440M -$1.061M -$2.710M
YoY Change -46.86% -24.51% -56.36%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$28.80M -$26.50M -$67.75M
COMMON SHARES
Basic Shares Outstanding 93.72M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2012 Q2 2012 Q1 2011 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.000M $3.210M $3.610M
YoY Change -44.6% -33.95% -55.04%
Cash & Equivalents $2.001M $3.207M $3.610M
Short-Term Investments
Other Short-Term Assets $1.550M $1.740M $1.450M
YoY Change 6.9% 31.82% 11.54%
Inventory
Prepaid Expenses $1.549M $1.735M $1.446M
Receivables
Other Receivables
Total Short-Term Assets $3.550M $4.943M $5.056M
YoY Change -29.79% -20.02% -45.81%
LONG-TERM ASSETS
Property, Plant & Equipment $5.857K $6.454K $3.782K
YoY Change 54.87%
Goodwill
YoY Change
Intangibles $3.394M $3.680M $3.525M
YoY Change -3.71%
Long-Term Investments
YoY Change
Other Assets $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $3.405M $3.692M $3.541M
YoY Change -3.84% -24.81% -22.69%
TOTAL ASSETS
Total Short-Term Assets $3.550M $4.943M $5.056M
Total Long-Term Assets $3.405M $3.692M $3.541M
Total Assets $6.955M $8.635M $8.597M
YoY Change -19.1% -22.14% -38.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $594.5K $804.8K $559.5K
YoY Change 6.25% 57.8% -0.08%
Accrued Expenses $369.7K $529.1K $509.8K
YoY Change -27.48% 1.74% -12.1%
Deferred Revenue
YoY Change
Short-Term Debt $2.200M $2.200M $2.200M
YoY Change 0.0% 0.46% 0.46%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.163M $3.533M $3.268M
YoY Change -3.22% 9.38% -1.85%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $99.73K $99.73K $99.73K
YoY Change 0.0% -89.72% -96.16%
Total Long-Term Liabilities $99.73K $99.73K $99.73K
YoY Change 0.0% -89.72% -96.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.163M $3.533M $3.268M
Total Long-Term Liabilities $99.73K $99.73K $99.73K
Total Liabilities $3.502M $4.036M $4.079M
YoY Change -14.16% -3.69% -31.21%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $941.1K $918.7K $777.7K
YoY Change 21.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.453M $4.599M $4.517M
YoY Change
Total Liabilities & Shareholders Equity $6.955M $8.635M $8.597M
YoY Change -19.1% -22.14% -38.2%

Cashflow Statement

Concept 2012 Q2 2012 Q1 2011 Q2
OPERATING ACTIVITIES
Net Income -$1.440M -$1.061M -$2.710M
YoY Change -46.86% -24.51% -56.36%
Depreciation, Depletion And Amortization $70.00K $70.00K $30.00K
YoY Change 133.33% 75.0% -25.0%
Cash From Operating Activities -$1.110M -$980.0K -$1.020M
YoY Change 8.82% -24.03% -61.36%
INVESTING ACTIVITIES
Capital Expenditures -$110.0K -$110.0K -$250.0K
YoY Change -56.0% -38.89% 108.33%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$110.0K -$110.0K -$250.0K
YoY Change -56.0% -38.89% -126.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.00K 2.750M 20.00K
YoY Change -50.0% 84.56% -99.81%
NET CHANGE
Cash From Operating Activities -1.110M -980.0K -1.020M
Cash From Investing Activities -110.0K -110.0K -250.0K
Cash From Financing Activities 10.00K 2.750M 20.00K
Net Change In Cash -1.210M 1.660M -1.250M
YoY Change -3.2% 8200.0% -113.83%
FREE CASH FLOW
Cash From Operating Activities -$1.110M -$980.0K -$1.020M
Capital Expenditures -$110.0K -$110.0K -$250.0K
Free Cash Flow -$1.000M -$870.0K -$770.0K
YoY Change 29.87% -21.62% -69.44%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
93721828 shares
CY2011Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4860893
CY2012Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3532949
CY2012Q1 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
CY2012Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
529060
CY2012Q1 us-gaap Assets
Assets
8634583
CY2012Q1 us-gaap Common Stock Value
CommonStockValue
918722
CY2012Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
91872182 shares
CY2012Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q1 us-gaap Assets Current
AssetsCurrent
4942723
CY2012Q1 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
65831588
CY2012Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
99728
CY2012Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1735472
CY2012Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3207251
CY2012Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
402900
CY2012Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
69511823
CY2012Q1 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
2199108
CY2012Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8634583
CY2012Q1 us-gaap Stockholders Equity
StockholdersEquity
4599006
CY2012Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
91872182 shares
CY2012Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6454
CY2012Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2012Q1 us-gaap Liabilities
Liabilities
4035577
CY2012Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
5171
CY2012Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
804781
CY2012Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3680235
CY2010Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8026296
CY2011Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3268439
CY2011Q2 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
CY2011Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
509806
CY2011Q2 us-gaap Assets
Assets
8596889
CY2011Q2 us-gaap Common Stock Value
CommonStockValue
777697
CY2011Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77769677 shares
CY2011Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2011Q2 us-gaap Assets Current
AssetsCurrent
5056018
CY2011Q2 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
60748435
CY2011Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
99728
CY2011Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1446064
CY2011Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3609954
CY2011Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
711259
CY2011Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2011Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
64488152
CY2011Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
2199108
CY2011Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8596889
CY2011Q2 us-gaap Stockholders Equity
StockholdersEquity
4517463
CY2011Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77769677 shares
CY2011Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2011Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3782
CY2011Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2011Q2 us-gaap Liabilities
Liabilities
4079426
CY2011Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
12358
CY2011Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
559525
CY2011Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3524731
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
115869
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-436967
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-115869
us-gaap Costs And Expenses
CostsAndExpenses
5078229
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4367896
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
2398794
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1639460
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
131312
us-gaap Share Based Compensation
ShareBasedCompensation
568025
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-78720
us-gaap Net Income Loss
NetIncomeLoss
-4557147
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3135200
us-gaap Increase Decrease In Fair Value Of Unhedged Derivative Instruments
IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments
453209
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6955941
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-60737
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2026
us-gaap Depreciation And Amortization
DepreciationAndAmortization
105547
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
434941
us-gaap Operating Income Loss
OperatingIncomeLoss
-5078229
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
6045
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-47139
us-gaap Revenue From Grants
RevenueFromGrants
244479
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3165403
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
15077
us-gaap Interest Paid
InterestPaid
79373
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
453209
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1943029
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1639460
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
snt Preferred Dividends Accrued Not Yet Paid
PreferredDividendsAccruedNotYetPaid
252500
snt Weighted Average Number Basic Diluted Shares Outstanding
WeightedAverageNumberBasicDilutedSharesOutstanding
66731159 shares
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Trading Symbol
TradingSymbol
SNT
dei Entity Registrant Name
EntityRegistrantName
SENESCO TECHNOLOGIES INC
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2012-03-31
dei Entity Central Index Key
EntityCentralIndexKey
0001035354
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
us-gaap Dividends
Dividends
242250
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
609875
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-343675
us-gaap Revenues
Revenues
200000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
148383
us-gaap Costs And Expenses
CostsAndExpenses
4045012
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3277907
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1455940
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
3218879
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
1555
us-gaap Share Based Compensation
ShareBasedCompensation
609875
us-gaap Depreciation And Amortization
DepreciationAndAmortization
185499
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
339214
us-gaap Operating Income Loss
OperatingIncomeLoss
-3845012
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
245256
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-402703
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
289408
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="FONT: 10pt Times New Roman, Times, Serif"> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Note 1 - Basis of Presentation:</b></p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#xA0;</p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The financial statements included herein have been prepared by Senesco Technologies, Inc. (the &#x201C;Company&#x201D;), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with United States generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended June 30, 2011, as amended.</p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#xA0;</p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In the opinion of the Company&#x2019;s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting solely of those which are of a normal recurring nature, necessary to present fairly its financial position as of March 31, 2012, the results of its operations and cash flows for the three months and nine months ended March 31, 2012 and 2011.</p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#xA0;</p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Interim results are not necessarily indicative of results for the full fiscal year.</p> </div>
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-100744
us-gaap Net Income Loss
NetIncomeLoss
-3627213
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1926492
us-gaap Increase Decrease In Fair Value Of Unhedged Derivative Instruments
IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments
308359
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5083153
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-90560
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
122252
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3367262
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4461
us-gaap Interest Paid
InterestPaid
96567
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
308359
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3218879
us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
-7187
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
snt Preferred Dividends Accrued Not Yet Paid
PreferredDividendsAccruedNotYetPaid
119998
snt Weighted Average Number Basic Diluted Shares Outstanding
WeightedAverageNumberBasicDilutedSharesOutstanding
83000064 shares
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2118520
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
115869
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6302557
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
205390
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
2199108
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
651781
us-gaap Revenues
Revenues
1790000
us-gaap Costs And Expenses
CostsAndExpenses
51604903
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35914248
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
10000000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
10333754
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
25318146
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
53800
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
1588087
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
586442
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
208886
us-gaap Share Based Compensation
ShareBasedCompensation
11949824
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
461811
us-gaap Other Noncash Expense
OtherNoncashExpense
131250
us-gaap Net Income Loss
NetIncomeLoss
-55497834
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20595850
us-gaap Increase Decrease In Fair Value Of Unhedged Derivative Instruments
IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments
8166026
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-65831588
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
320496
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
184666
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-361877
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1027781
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
2160986
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
6117891
us-gaap Operating Income Loss
OperatingIncomeLoss
-49814903
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
804781
us-gaap Revenue From Grants
RevenueFromGrants
244479
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3207251
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1735472
us-gaap Interest Paid
InterestPaid
333701
us-gaap Interest Expense Debt
InterestExpenseDebt
2027930
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
8487285
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
31009053
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
11227870
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
45424056
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1227869
us-gaap Noncash Contribution Expense
NoncashContributionExpense
85179
us-gaap Paid In Kind Interest
PaidInKindInterest
2003386
us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
5171
snt Proceeds From Government Grant
ProceedsFromGovernmentGrant
99728
snt Preferred Dividends Accrued Not Yet Paid
PreferredDividendsAccruedNotYetPaid
242250
snt Proceeds From Issuance Of Preferred Stock And Warrants Net
ProceedsFromIssuanceOfPreferredStockAndWarrantsNet
10754841
snt Warrants Issued For Financing Costs
WarrantsIssuedForFinancingCosts
690984
CY2011Q1 us-gaap Costs And Expenses
CostsAndExpenses
1367801
CY2011Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
716780
CY2011Q1 us-gaap Net Income Loss
NetIncomeLoss
-1405108
CY2011Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
800341
CY2011Q1 us-gaap Increase Decrease In Fair Value Of Unhedged Derivative Instruments
IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments
-16177
CY2011Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2121888
CY2011Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-21130
CY2011Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1367801
CY2011Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
567460
CY2011Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2011Q1 snt Weighted Average Number Basic Diluted Shares Outstanding
WeightedAverageNumberBasicDilutedSharesOutstanding
74904192 shares
CY2012Q1 us-gaap Costs And Expenses
CostsAndExpenses
1108729
CY2012Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
419480
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-1060659
CY2012Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
540789
CY2012Q1 us-gaap Increase Decrease In Fair Value Of Unhedged Derivative Instruments
IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments
76048
CY2012Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1480139
CY2012Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-27978
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1108729
CY2012Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
567940
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2012Q1 snt Weighted Average Number Basic Diluted Shares Outstanding
WeightedAverageNumberBasicDilutedSharesOutstanding
88942763 shares

Files In Submission

Name View Source Status
0001144204-12-028430-index-headers.html Edgar Link pending
0001144204-12-028430-index.html Edgar Link pending
0001144204-12-028430.txt Edgar Link pending
0001144204-12-028430-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snt-20120331.xml Edgar Link completed
snt-20120331.xsd Edgar Link pending
snt-20120331_cal.xml Edgar Link unprocessable
snt-20120331_def.xml Edgar Link unprocessable
snt-20120331_lab.xml Edgar Link unprocessable
snt-20120331_pre.xml Edgar Link unprocessable
v312232_10q.htm Edgar Link pending
v312232_ex10-1.htm Edgar Link pending
v312232_ex31-1.htm Edgar Link pending
v312232_ex31-2.htm Edgar Link pending
v312232_ex32-1.htm Edgar Link pending
v312232_ex32-2.htm Edgar Link pending